

Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality

Kanser Hastalarındaki Enfeksiyon Ataklarının Prospektif Değerlendirmesi: Mikrobiyolojik Özellikler ve Mortalite için Risk Faktörleri

Nursel Çalık Başaran¹, Ergun Karaağaoğlu², Gülşen Hasçelik³, Mine Durusu Tanrıöver¹, Murat Akova⁴

¹Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey

²Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey

³Hacettepe University Faculty of Medicine, Department of Basic Microbiology, Ankara, Turkey

⁴Hacettepe University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey

Abstract

Objective: We aimed to determine the frequency, type, and etiology of infections and the risk factors for infections and mortality in hospitalized cancer patients.

Materials and Methods: We prospectively enrolled adult cancer patients hospitalized in the internal medicine wards of a tertiary care academic center between January and August 2004. Patients were followed during their hospitalization periods for neutropenia, infections, culture results, and mortality.

Results: We followed 473 cancer patients with 818 hospitalization episodes and 384 infection episodes in total. Seventy-nine percent of the infections were nosocomial, and febrile neutropenia (FN) was observed in 196 (51%) of the infection episodes. Bacteremia was found in 29% of FN episodes and in 8% of nonneutropenic patients. Gram-positive bacteria were the leading cause of bacteremia in both neutropenic and nonneutropenic cases (70% and 58%, respectively). Presence of an indwelling central catheter increased bacteremia risk by 3-fold. The overall mortality rate was 17%, whereas 34% of the patients with bloodstream infections died. Presence of bacteremia and advanced disease stage increased overall mortality by 6.1-fold and 3.7-fold, respectively.

Conclusion: Nearly half of the cancer patients developed an infection during their hospital stays, with gram-positive bacteria being the predominant etiologic microorganisms. This demonstrates the changing trends in infections considering that, until 2004, gram-negative bacteria were the most predominant microorganisms among cancer patients in our institute.

Keywords: Febrile neutropenia, Cancer, Mortality, Risk factors

Öz

Amaç: Enfeksiyonlar, kanser hastalarında önde gelen morbidite ve mortaliteleri nedeni olmuşlardır. Bu çalışmada hastanede yatan kanser hastalarında enfeksiyonların sıklığını, tiplerini, etiyolojilerini ve enfeksiyon gelişimi ve mortalite için risk faktörlerini belirlemeyi amaçladık.

Gereç ve Yöntemler: Üçüncü basamak bir üniversite hastanesinin iç hastalıkları servislerinde Ocak-Ağustos 2004 tarihleri arasında izlenmiş olan erişkin kanser hastaları dahil edildi. Yatış süreleri boyunca nötropeni, enfeksiyonlar, kültür sonuçları ve mortalite açısından prospektif olarak izlendiler.

Bulgular: Toplam 473 kanser hastasının 818 hastaneye yatış atağı izlendi. Toplam 818 yatış atağı sırasında 384 (%46) enfeksiyon atağı gözlemlendi- %79'u nosokomiyaldi. Febril nötropeni (FN) tüm atakların 196'sında (%51) görüldü. Bakteremi, FN ataklarının %29'unda ve nötropenik olmayan hastaların %8'inde görüldü. Gram-pozitifler hem nötropenik olan hem de olmayan hastalardaki bakteremilerin önde gelen etkeni olarak görüldü (%70 ve %58, sırasıyla). Santral kateter varlığının bakteremi riskini 3 kat artırdığı görüldü. Toplam mortalite %17 iken bakteremisi olan hastalarda mortalite %34 saptandı. Bakteremi varlığı ve ileri evre hastalık toplam mortaliteyi, sırasıyla, 6,1 ve 3,7 kat artırmaktaydı.

Sonuç: Hastanede yatan kanser hastalarının neredeyse yarısında en azından bir enfeksiyon gelişmektedir ve bu enfeksiyonlarda gram-pozitifler hakimdir. Bu bilgiler, 2004 yılına kadar kanser hastalarında en sık görülen mikroorganizmaların gram-negatif mikroorganizmalar olduğu göz önüne alındığında, enfeksiyonlarda değişen eğilimler olduğunu göstermektedir.

Anahtar Sözcükler: Febril nötropeni, Kanser, Mortalite, Risk faktörleri



Introduction

Infections have become the leading cause of mortality and morbidity of cancer while supportive and curative treatment strategies prolong life [1,2]. Cancer and its treatment suppress the immune system, and long and recurrent hospitalizations predispose patients to various infections.

Predominant infectious pathogens have been variable in time with changing cancer treatment strategies, antibacterial prophylaxis practices, and emerging resistance patterns in bacteria. Until the 1980s, the leading microorganisms in cancer patients were enteric gram-negative bacteria and *Pseudomonas aeruginosa*. As of the 1980s, gram-positive bacteria became the most common pathogens in these patients [1,3,4]. However, recently, nonfermenting gram-negative bacteria have emerged as the leading pathogens in cancer patients.

It is important to know the risk factors for infections, changing epidemiology, and resistance patterns of pathogenic microorganisms for the proper management of infections in cancer patients. In this study, we aimed to determine the frequency, type, and etiology of infections and the risk factors for infections and mortality in hospitalized cancer patients.

Materials and Methods

Study Design and Patients

This study was done in the internal medicine wards of a tertiary care university hospital. The institutional review board approved the study and adult cancer patients hospitalized between January and August 2004 were enrolled and followed prospectively. Demographic data, cancer type and stage, previous stem cell transplantation history and type, comorbidities, and presence of antibacterial utilization in the previous month were recorded upon admission. Presence of indwelling catheters (central or peripheral venous, arterial, urinary, or drainage), presence of parenteral nutrition, requirement of intensive care unit and mechanical ventilation, therapy for cancer (chemotherapy, radiation, corticosteroids), vital signs, infections, antibiotic usage, culture results, and neutrophil counts were recorded throughout the admission episode. Descriptive data and further analyses were done based on the admission episodes unless otherwise specified. One patient might have had more than one admission. The infectious diseases department followed the patients and the researchers did not intervene in the diagnostic and therapeutic processes.

Neutropenia was defined as an absolute neutrophil count below 500/mm³ or below <1000/mm³ and expected to decline rapidly. Neutropenic infections were classified as clinically or microbiologically documented infection, bloodstream infection (BSI), or fever of unknown origin [5]. Infections were

classified as nosocomial according to the 1998 definitions of the Centers for Disease Control and Prevention [6]. Metastatic solid tumors, newly diagnosed hematological malignancies with poor prognosis, and relapsed or treatment-resistant hematological malignancies were defined as advanced disease stage. Corticosteroid use was defined as the use of prednisolone at a dose of >20 mg/day (or equivalent) or over a period of 10 days whatever the dose was. Antifungal prophylaxis was defined as oral fluconazole/itraconazole used in prophylactic doses.

Microbiological Methods

All the cultures were collected from different parts of the body according to the presumed infections. They were inoculated onto suitable media and incubated at 37 °C for 24–48 h. Catheter cultures were studied quantitatively. For blood cultures, a BD BACTEC 9000 Blood Culture System (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) was used. All the microorganisms were identified by gram staining, conventional microbiological tests (such as hemolysis, catalase, oxidase, and coagulase reaction), and the Phoenix System (Becton Dickinson Diagnostic Systems). Antibiotic susceptibility tests were conducted with the Phoenix System and for *Streptococcus pneumoniae* by E-test (AB BIODISK, Solna, Sweden). Results were evaluated according to the Clinical and Laboratory Standards Institute 2004 standards.

Statistical Analysis

Data were analyzed by SPSS 11.5 for Windows (SPSS Inc., Chicago, IL, USA). Distribution of data was analyzed by Kolmogorov-Smirnov test. Normally distributed data are presented as mean ± standard deviation, while abnormally distributed data are presented as median (minimum–maximum). Categorical variables were compared by chi-square test and Fischer's exact test where appropriate, and continuous variables were analyzed by Student's t-test. Risk analysis was performed by Fisher's exact chi-square test and parameters that were found to be significant were introduced into a multivariate logistic regression model. Relative risk was computed for possible risk factors with 95% confidence interval and p<0.05 was accepted as statistically significant.

Results

During the study period, 473 cancer patients between 16 and 82 years of age were enrolled and 818 hospitalization episodes were followed prospectively. Of these patients, 286 (60%) were male and the mean age was 51 years (16–82 years). Chronic diseases accompanying admission episodes were as follows: 4.8% coronary artery disease, 2.7% chronic renal failure, 10.2% diabetes mellitus, and 13.4% hypertension. Solid organ cancer was seen in 254 (53%) patients while the remaining had hematological diseases (Table 1). Hematopoietic stem cell transplantation (HSCT) was done in 49 patients with 63

admission episodes (7.7%) and half of them were allogeneic HSCTs.

In the course of 818 hospitalization episodes, a total of 384 (46%) infection episodes were observed and 79% of these were nosocomial. Febrile neutropenia (FN) was observed in 126 patients having 196 (51%) infection episodes. Acute myeloid leukemia was the most common underlying disease (n=35, 35/126, 27%) in patients with FN. Mean duration of

neutropenia was longer in patients with an infection (16.2 days) when compared to those without an infection (8.2 days) (p=0.002). Bacteremia was found in 29% of FN episodes and in 8% of nonneutropenic infections (p<0.05). Sites of infections in neutropenic and nonneutropenic patients are shown in Table 2. The mean hospitalization duration was three times longer for patients with infection (38±31 days) when compared to the mean of the total hospitalization episodes (13±23 days).

Table 1. Demographic features of all patients and particularly patients with an infection.

Patient Characteristics	All Patients (n=473) n (%)	Patients with Infection (n=272) n (%)	
Age (years)*	51±16	51±16	
Male sex	286 (60.5)	161 (59.2)	
Duration of hospitalization (days)*	13±23	38±31	
Malignancy			
Hematological diseases	219 (46.3)	158 (58)	
	Non-Hodgkin lymphoma	82 (17)	54 (19.9)
	Acute myeloblastic leukemia	43 (9.1)	36 (13.2)
	Acute lymphoblastic leukemia	17 (3.6)	14 (5.1)
	Multiple myeloma	35 (7.4)	23 (8.5)
	Hodgkin disease	12 (2.5)	8 (2.9)
	Chronic lymphocytic leukemia	13 (2.8)	6 (2.2)
	Chronic myelocytic leukemia	5 (1.1)	5 (1.8)
	Myelodysplastic syndrome	8 (1.7)	8 (2.9)
	Aplastic anemia	4 (0.8)	4 (1.5)
Solid organ malignancies	254 (53.7)	114 (41.9)	
	Lung cancer/malignant pleural mesothelioma	69 (14.6)	30 (11)
	Colorectal carcinoma	37 (7.8)	15 (5.5)
	Head and neck cancer	24 (5)	5 (1.8)
	Esophagus/gastric cancer	23 (4.9)	9 (3.3)
	Breast cancer	16 (3.4)	8 (2.9)
	Cancer of unknown primary origin	13 (2.7)	6 (2.2)
	Pancreas cancer	9 (1.9)	5 (1.8)
	Ovarian cancer	8 (1.7)	4 (1.5)
	Testicular cancer	7 (1.5)	5 (1.8)
	Thyroid/adrenal/neuroendocrine tumor	5 (1.1)	2 (0.7)
	Sarcoma	5 (1.1)	4 (1.5)
	Malign mesenchymal tumor	4 (0.8)	2 (0.7)
	Endometrium cancer	3 (0.6)	2 (0.7)
	Cervical cancer	4 (0.8)	3 (1.1)
	Bladder cancer	3 (0.6)	3 (1.1)
	Prostate cancer	1 (0.2)	1 (0.4)
	Renal cell cancer	4 (0.8)	2 (0.7)
	Intracranial tumor	3 (0.6)	3 (1.1)
	Malignant melanoma	3 (0.6)	1 (0.4)

*Mean ± standard deviation.

Fluconazole as antifungal prophylaxis was given in 63 (7.7%) episodes as a part of the stem cell transplantation regimen. Corticosteroids were used in 215 (26.4%) of the admission episodes. Radiation therapy was performed in 5.1% (42) of hospitalization episodes. Unfortunately, we had no data about granulocyte colony-stimulating factor use in this study.

Nonneutropenic episodes constituted 71.4% of all the hospitalization episodes and in 77.3% of these cases an immunosuppressive treatment, including corticosteroids, was used. As expected, there was an immunosuppressive treatment in 94% of neutropenic episodes (p<0.001). Among the nonneutropenic episodes, infections were more frequently seen in those patients receiving any immunosuppressive treatment than in episodes with no immunosuppressive treatment (p<0.001). However, there was no difference in terms of mortality (p=0.111).

At least one pathogenic microorganism was isolated from culture specimens obtained from patients during 187 (48.6%) infection episodes. Blood cultures were positive in 29.6% of all the patients and in 60.6% of neutropenic patients. Gram-negative microorganisms were the most common (51%) isolates among all the specimens, whereas gram-positive microorganisms were the most common (65%) among blood culture isolates (Table 3). Fungi were isolated in 5% of all the specimens and 9% of the specimens from neutropenic patients. When bacteremic episodes were considered, gram-positive bacteria were the leading cause in both neutropenic and nonneutropenic cases (70% and 58%, respectively; p<0.05) (Table 4).

Table 2. Distribution of infection sites in neutropenic and nonneutropenic patients.

Infection sites	n (%)
Neutropenic episodes (n=206)	
Fever of unknown origin	72 (34)
Bloodstream infection	59 (29)
Microbiologically documented infection (other than bloodstream)	14 (7)
Clinical infection	61 (30)
Nonneutropenic episodes (n=279)	
Respiratory infection	94 (3)
Urinary tract infection	64 (22.9)
Gastrointestinal system infection	52 (18)
Skin and soft tissue infection	42 (15)
Bloodstream infection	21 (8)
Central nervous system infection	4 (1.4)
Skeletal system infection	2 (0.7)

Some patients may have had more than one neutropenic episode within one hospital admission. "n" refers to number of infection episodes and % is the percentage within neutropenic or nonneutropenic episodes.

The resistance patterns of *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli*, *Klebsiella* spp., and *Pseudomonas* spp. are listed in Table 5. In neutropenic patients, rates of extended-spectrum β-lactamase (ESBL)-producing *E. coli* and *Klebsiella* spp. were found to be high compared to nonneutropenic patients (p<0.05).

Table 3. The results of blood cultures and all cultures.

	Blood Cultures	All Cultures
Name of microorganism	n (%)	n (%)
<i>Staphylococcus aureus</i>	8 (5)	26 (4.8)
<i>Staphylococcus aureus</i> (MR)	2 (1.2)	9 (1.6)
Coagulase-negative staphylococci	11 (7)	17 (3.1)
Coagulase-negative staphylococci (MR)	67 (42)	103 (19.2)
<i>Streptococcus pneumoniae</i>	1 (0.6)	7 (1.3)
<i>Streptococcus viridans</i>	2 (1.2)	4 (0.7)
<i>Streptococcus pyogenes</i>	3 (1.9)	1 (0.1)
<i>Streptococcus agalactiae</i>	2 (1.2)	5 (0.9)
<i>Enterococcus faecalis</i>	2 (1.2)	30 (5.5)
<i>Enterococcus faecium</i>	3 (1.9)	9 (1.6)
<i>Enterococcus gallinarum/casseliflavus</i>	0	2 (0.3)
<i>Corynebacterium</i> spp.	1 (0.6)	2 (0.3)
Gram-positive bacteria: total	102 (65)	215 (40)
<i>Moraxella catarrhalis</i>	0	1 (0.1)
<i>Haemophilus influenza</i>	1 (0.6)	8 (1.4)
<i>Escherichia coli</i>	8 (5)	80 (14.9)
<i>Escherichia coli</i> (ESBL+)	6 (3.8)	33 (6.1)
<i>Klebsiella pneumoniae</i>	2 (1.2)	19 (3.5)
<i>Klebsiella oxytoca</i>	4 (2.5)	17 (3.1)
<i>Klebsiella pneumoniae</i> (ESBL+)	4 (2.5)	9 (1.6)
<i>Klebsiella oxytoca</i> (ESBL+)	0	2 (0.3)
<i>Proteus vulgaris</i>	0	7 (1.3)
<i>Enterobacter</i> spp.	2 (1.2)	15 (2.7)
<i>Salmonella</i> spp.	3 (1.9)	3 (0.5)
<i>Pseudomonas aeruginosa</i>	11 (7)	49 (9.1)
<i>Acinetobacter baumannii</i>	2 (1)	13 (2.4)
Other <i>Acinetobacter</i> spp.	0	3 (0.5)
<i>Stenotrophomonas maltophilia</i>	3 (1.9)	9 (1.6)
<i>Aeromonas</i> spp.	1 (0.6)	3 (0.5)
<i>Citrobacter</i> spp.	0	2 (0.3)
Gram-negative bacteria: total	47 (30)	273 (51)
<i>Candida albicans</i>	6 (3.8)	41 (7.6)
<i>Candida tropicalis</i>	0	2 (0.3)
<i>Trichosporon</i> spp.	2 (1.2)	2 (0.3)
<i>Aspergillus</i> spp.	0	1 (0.1)
<i>Candida glabrata/krusei</i>	0	2 (0.3)
Fungi: total	8 (5)	48 (9)

MR: Methicillin-resistant, ESBL+: extended-spectrum β-lactamase positive.

Possible risk factors for infection in cancer patients were analyzed by univariate analysis and then the risk factors found to increase the occurrence of an infection were introduced into a multivariate logistic regression model (Table 6). We found that advanced disease stage, neutropenia for more than 7 days, and radiation were related to an increased frequency of infection in cancer patients ($p<0.05$). Presence of an indwelling central catheter increased bacteremia risk by 3-fold (Table 6).

The overall mortality rate was 17%, whereas 34% of patients with BSIs died ($p<0.05$). Among patients with FN, the mortality rate was 18.4%, and the occurrence of a BSI increased the mortality rate to 41%. Presence of bacteremia increased overall mortality 6.1 times and advanced disease stage increased overall mortality 3.7 times. On the other hand, usage of prophylactic antifungal therapy decreased mortality 3.3-fold, but the p -value was found to be statistically insignificant ($p=0.055$)

(Table 6). Comorbid chronic diseases had no significant effect on infection or mortality.

Discussion

This study is a landmark study to show the shift of infectious etiologies in cancer patients from gram-negative to gram-positive bacteria. Afterwards, a long-term multicentric study was established in Turkey for microbiological surveillance of FN patients. Such surveillance studies are valuable to implement systemic changes in individual institutions and countries.

In this prospective observational study we found that 46% of all cancer patients developed at least one infection and 85% of neutropenic patients developed at least one FN attack during their index hospital stay. Among the neutropenic attacks, 65% were documented clinically or microbiologically, and the

Microorganisms	Neutropenic, n (%)	Nonneutropenic, n (%)	p-value
Coagulase-negative staphylococci (MR)	58 (50.8)	9 (21)	<0.05
Coagulase-negative staphylococci	6 (5.3)	5 (12)	0.4
<i>Staphylococcus aureus</i>	3 (2.6)	5 (12)	
<i>Streptococcus pyogenes</i>	3 (2.6)	0	
<i>Enterococcus faecalis</i>	3 (2.6)	1 (2)	
<i>Staphylococcus aureus</i> (MR)	2 (1.75)	0	
<i>Enterococcus faecium</i>	2 (1.75)	2 (4.6)	
Viridans group streptococci	1 (0.9)	1 (2)	
<i>Streptococcus agalactiae</i>	1 (0.9)	1 (2)	
<i>Corynebacterium</i> spp.	1 (0.9)	0	
<i>Streptococcus pneumoniae</i>	0	1 (2)	
Gram-positive bacteria: total	80 (70)	25 (58)	<0.05
<i>Escherichia coli</i>	6 (5.3)	2 (4.6)	
<i>Escherichia coli</i> (ESBL+)	4 (3.5)	2 (4.6)	
<i>Pseudomonas aeruginosa</i>	6 (5.3)	5 (12)	
<i>Klebsiella pneumoniae</i> (ESBL+)	4 (3.5)	0	
<i>Klebsiella pneumoniae</i>	2 (1.75)	0	
<i>Stenotrophomonas maltophilia</i>	3 (2.6)	0	
<i>Enterobacter cloaca</i>	2 (1.75)	0	
<i>Klebsiella oxytoca</i>	1 (0.9)	3 (7)	
<i>Acinetobacter baumannii</i>	1 (0.9)	1 (2)	
<i>Aeromonas</i> spp.	1 (0.9)	0	
<i>Haemophilus influenzae</i>	0	1 (2)	
Gram-negative bacteria: total	30 (26.5)	14 (33)	<0.05
<i>Candida</i> spp.	4 (3.5)	2 (4.6)	
<i>Trichosporon</i> spp.	0	2 (4.6)	
Fungi: total	4 (3.5)	4 (9)	
Total	114 (100)	43 (100)	<0.05

MR: Methicillin-resistant, ESBL: extended-spectrum β -lactamase.

Table 5. Resistance patterns of microorganisms in neutropenic and nonneutropenic patients.

	Resistance	Total, n (%)	Nonneutropenic, n (%)	Neutropenic, n (%)	p-value
<i>Escherichia coli</i>	ESBL (-)	80 (70.7)	72 (75.7)	8 (44.4)	
	ESBL(+)	33 (29.3)	23 (24.3)	10 (55.6)	<0.05
<i>Klebsiella spp.</i>	ESBL (-)	36 (76.5)	30 (85.7)	6 (50)	
	ESBL (+)	11 (23.5)	5 (14.3)	6 (50)	<0.05
<i>Staphylococcus aureus</i>	MS	26 (74)	18 (72)	8 (80)	
	MR	9 (26)	7 (28)	2 (20)	NA
<i>Staphylococcus epidermidis</i>	MS	2 (3.7)	2 (10.5)	0 (0)	
	MR	52 (96.3)	17 (89.5)	35 (100)	NA
<i>Pseudomonas aeruginosa</i>	MDR (-)	23 (71.8)	18 (75)	5 (62.5)	
	MDR (+)	9 (28.2)	6 (25)	3 (37.5)	NA

ESBL: Extended-spectrum β-lactamase, MR: methicillin-resistant, MS: methicillin-sensitive, MDR: multidrug-resistant.

Table 6. Risk factors for infection, bloodstream infection, and mortality.

	Infection		Bloodstream Infection		Mortality	
	RR (95% CI)	p-value	RR (95% CI)	p-value	RR (95% CI)	p-value
Advanced disease stage	3.1 (1.3-7.3)	0.009	-	-	3.7 (1.2-11.6)	0.021
Duration of neutropenia >7 days	3.9 (1.6-9.5)	0.002	-	-	-	-
Radiation	3.5 (1.2-7.6)	0.017	-	-	-	-
Indwelling central venous catheter	-	-	3.0 (1.0-8.0)	0.042	-	-
Antifungal prophylaxis	-	-	-	-	0.3 (0.09-1.0)	0.055
Bloodstream infection	-	-	-	-	6.1 (2.8-13.2)	<0.001

RR: Relative risk, CI: confidence interval.

BSI rate was 29% among the FN attacks, comparable to that reported in numerous other studies [5,7,8,9]. Compared to previous surveillance data from our hospital, both documented clinical infection and BSI rates were increased, which might be attributed to increased awareness of FN and appropriate blood culture techniques [10,11]. The definition of BSI may also have an influence on infection rates; the criteria used for skin flora organisms to be pathogens may be a reason for increased BSI rate.

Methicillin-resistant coagulase-negative staphylococci (MR-CoNS) were the most commonly isolated microorganisms from overall and blood culture specimens. The predominance of gram-positive bacteria and MR-CoNS in BSIs in this cohort was parallel to findings in the literature. In cancer patients BSIs were due to gram-negative enteric bacteria and *Pseudomonas aeruginosa* in the 1960s and 1970s, but by the middle of the 1980s gram-positive bacteria had become predominant [12,13]. Memorial Sloan-Kettering Cancer Center reported that the incidence of gram-positive BSIs increased from 14% to 23% between 1977 and 1987 [1,8]. During the same time period, both the European Organisation for Research and Treatment of Cancer (EORTC) and the Febrile Neutropenia Study Group reported that 55%-60% of BSIs were due to gram-positive microorganisms [14]. In 2003,

Wisplinghoff et al. reported that in cancer patients nosocomial BSIs in 32% of neutropenic cases and 33% of nonneutropenic cases were due to CoNS [3]. Srinivasan et al. reported that in stem cell transplantation recipients, gram-positive bacteria, and especially members of skin flora such as *Staphylococcus epidermidis*, were predominant in BSIs [9]. Mikulska et al. reported the gram-positive to gram-negative ratio as 60%:40% in BSI infections of cancer patients [15]. In our study, the MR-CoNS ratio was the ratio between the blood cultures, so repetitive isolations from a patient should be kept in mind. We also accepted a CoNS as a pathogen when ≥1 blood culture was positive in the presence of fever or hypothermia, hypotension, indwelling catheter, or antibiotics, which could differ from other studies in the literature [1].

Recent studies revealed that in hematological malignancies gram-negative microorganisms have again become the most relevant microorganisms in BSIs. Cattaneo et al. reported a predominance of gram-negative bacteria (57.3%) in hematological malignancies between 2004 and 2010 [16]. Gudiol et al. reported that 49% of BSIs in hematological malignancies were due to gram-negative microorganisms and it was concluded that gram-positive microorganisms had decreased after quinolone prophylaxis [17]. A recently published

paper by Trecarichi et al. also reported the shift from gram-positive to gram-negative bacteria in BSIs in hematologic malignancies and again they pointed out the increasing resistance among gram-negative bacteria [18]. Several studies demonstrated gram-negative predominance either in blood or other specimen cultures in hematologic or solid cancer patients, with a frequency ranging between 24.7% and 75.8% in different geographic places with high resistance rates, including ESBL-positive *Enterobacteriaceae*, multidrug-resistant *Pseudomonas aeruginosa*, *Acinetobacter* spp., and *Stenotrophomonas maltophilia* [19,20,21,22]. According to surveillance data between 2005 and 2009 from our institution, gram-negative bacteria became the predominant BSI etiology in hematological malignancies with high resistance patterns [23]. Our study differs from these other studies in two major points: first, in our study, we followed both hematological and solid cancer patients, and second, we accepted at least one positive culture with CoNS in the presence of fever or central venous catheter. The growing resistance problems, especially among gram-negative pathogens, require special efforts in infection control measures and rational antibiotic usage in cancer patients.

In this study ESBL-positive *E. coli* (55%) and *Klebsiella* spp. (50%) were more frequent in neutropenic cases than nonneutropenic cases. A literature review revealed that ESBL positivity in cancer patients ranged from 12% to 75% for *E. coli* and *K. pneumoniae* in different studies [23,24,25,26,27,28,29]. It was also shown that ESBL positivity negatively affects mortality and morbidity [26,30,31]. Unfortunately, due to low case numbers, we could not analyze the mortality effect of resistant gram-negative bacteria.

We found that patients who were neutropenic for 7 or more days were prone to infection 3.9-fold more so than others. Poor prognosis and advanced stage solid or hematologic cancers were also related to an increased infection risk by 3.1-fold. Radiation was another risk factor for infection. This might be explained by the characteristics of the patient group that received radiotherapy: poor performance status, palliation in advanced disease, advanced age, or total body radiation prior to stem cell transplantation.

Indwelling central catheter was a risk factor for BSIs. In the last 30 years, increased use of persistent indwelling catheters has brought about an increased infection risk, especially for CoNS BSIs [1,12,32,33]. Moreover, BSI was a risk factor for mortality in our study. In previous studies mortality in cancer patients with BSIs ranged between 20% and 35% and this changed according to the pathogenic microorganisms [21,34,35,36,37,38]. This also points to the importance of implementing catheter bundles to decrease catheter-associated BSI rates.

Antifungal prophylaxis was part of the prophylaxis regimen in HSCT patients and it seemed to lower the mortality, although we could not show statistical significance. There are some reports showing azole-resistant breakthrough fungemia, but a recent study from the EORTC revealed that antifungal prophylaxis was protective in fungemia in cancer patients [39]. As there are various studies on different oral antifungal prophylaxes with different outcomes favoring posaconazole, itraconazole, or fluconazole use in high-risk patients, further studies are required about which drug to use for which patient and how long these drugs must be used [40,41,42].

Conclusion

Nearly half of the cancer patients developed an infection during their hospital stays, with gram-positive bacteria being the predominant etiologic microorganisms. This demonstrates the changing trends in infections considering that, until 2004, gram-negative bacteria were the most predominant microorganisms among cancer patients in our institute. Each patient must be evaluated individually for risk factors, and while antibiotic treatment is being planned, current local surveillance data and the resistance patterns of the microorganisms should be taken into account along with individual risk factors.

Acknowledgment

A part of this study was presented as a poster presentation at the Febrile Neutropenia Symposium, February 2005, Ankara, Turkey, and the Interscience Conference on Antimicrobial Agents and Chemotherapy, December 2005, Washington, DC, USA.

Ethics

Ethics Committee Approval: LUT 05/15; Informed Consent: It was taken.

Authorship Contributions

Concept: Nursel Çalık Başaran, Ergun Karaağaoğlu, Gülşen Haşçelik, Mine Durusu Tanrıöver, Murat Akova; Design: Nursel Çalık Başaran, Ergun Karaağaoğlu, Gülşen Haşçelik, Mine Durusu Tanrıöver, Murat Akova; Data Collection or Processing: Nursel Çalık Başaran, Ergun Karaağaoğlu, Gülşen Haşçelik, Mine Durusu Tanrıöver, Murat Akova; Analysis or Interpretation: Nursel Çalık Başaran, Ergun Karaağaoğlu, Gülşen Haşçelik, Mine Durusu Tanrıöver, Murat Akova; Literature Search: Nursel Çalık Başaran, Ergun Karaağaoğlu, Gülşen Haşçelik, Mine Durusu Tanrıöver, Murat Akova; Writing: Nursel Çalık Başaran, Ergun Karaağaoğlu, Gülşen Haşçelik, Mine Durusu Tanrıöver, Murat Akova.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

- Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. *Clin Infect Dis* 1993;17(Suppl 2):S322-328.
- Soave R, Sepkowitz KZ. The immunocompromised host. In: Reese RE, Betts RF (eds). *A Practical Approach to Infectious Diseases*, 3rd ed. Boston, Little, Brown & Co., 1991.
- Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis* 2003;36:1103-1110.
- Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. *N Engl J Med* 1993;328:1323-1332.
- Serody JS. Fever in immunocompromised patients. *N Engl J Med* 2000;342:217-218.
- Crowe MJ, Cooke EM. Review of case definitions for nosocomial infection--towards a consensus. Presentation by the Nosocomial Infection Surveillance Unit (NISU) to the Hospital Infection Liaison Group, subcommittee of the Federation of Infection Societies (FIS). *J Hosp Infect* 1998;39:3-11.
- Klastersky J. Management of fever in neutropenic patients with different risks of complications. *Clin Infect Dis* 2004;39(Suppl 1):S32-37.
- Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. *Infection* 2000;28:367-373.
- Srinivasan A, Wang C, Srivastava DK, Burnette K, Shenep JL, Leung W, Hayden RT. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2013;19:94-101.
- Akova M, Akan H, Korten V, Biberöglü K, Hayran M, Ünal S, Kars A, Kansu E. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. *Int J Antimicrob Agents* 1999;13:15-19.
- Erman M, Akova M, Akan H, Korten V, Ferhanoğlu B, Köksal I, Çetinkaya Y, Uzun Ö, Ünal S; Febrile Neutropenia Study Group of Turkey. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. *Scand J Infect Dis* 2001;33:827-831.
- Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. *Eur J Clin Microbiol Infect Dis* 1996;15:291-296.
- Whimby E, Kiehn TE, Brannon P, Blevins A, Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. *Am J Med* 1987;82:723-730.
- EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. *Eur J Cancer* 1990;26:569-574.
- Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, di Grazia C, Frassoni F, Bacigalupo A, Viscoli C. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. *Biol Blood Marrow Transplant* 2009;15:47-53.
- Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, D'Adda M, Morello E, Re A, Borlenghi E, Manca N, Rossi G. *P. aeruginosa* bloodstream infections among hematological patients: an old or new question? *Ann Hematol* 2012;91:1299-1304.
- Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cismal M, Domingo-Domenech E, Jimenez L, Carratala J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. *Clin Microbiol Infect* 2013;19:474-479.
- Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, Nosari A, Caira M, Spadea A, Busca A, Vianelli N, Tumbarello M; HeMABIS Registry-SEIFEM Group, Italy. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. *Clin Microbiol Infect* 2015;21:337-343.
- Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, Hsueh PR. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. *Epidemiol Infect* 2010;138:1044-1051.
- Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, Kapil A. Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. *Med Oncol* 2012;29:1354-1360.
- Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, Andrianaki AM, Falagas ME. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. *Support Care Cancer* 2013;21:2521-2526.
- Poon LM, Jin J, Chee YL, Ding Y, Lee YM, Chng WJ, Chai LY, Tan LK, Hsu LY. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. *Singapore Med J* 2012;53:720-725.
- Kara Ö, Zarakolu P, Aşçıoğlu S, Etgül S, Uz B, Büyükaşık Y, Akova M. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. *Infect Dis (Lond)* 2015;47:686-693.
- Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cismal M, Sanchez-Ortega I, Duarte R, Calvo M, Carratala J. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. *J Antimicrob Chemother* 2011;66:657-663.
- Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, Yoo JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS. *Escherichia coli* and *Klebsiella pneumoniae* bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. *Ann Hematol* 2013;92:533-541.
- Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by *Escherichia coli* in patients with hematological malignancies. *J Infect* 2009;58:299-307.
- Wang SS, Lee NY, Hsueh PR, Huang WH, Tsui KC, Lee HC, Wu CJ, Chang CM, Huang CC, Huang CF, Ko WC. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *J Microbiol Immunol Infect* 2011;44:282-288.
- Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, Akova M; Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. *J Infect* 2014;68:321-331.
- Zarakolu P, Metan G, Haşçelik G, Akova M. Prevalence of extended-spectrum beta-lactamases in nosocomial *Escherichia coli* and *Klebsiella* spp. strains isolated from blood cultures. *Mikrobiyol Bul* 2007;41:579-584a (in Turkish with English abstract).
- Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, Xie X. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infection: risk factors and clinical outcome. *Intensive Care Med* 2002;28:1718-1723.
- Kang CI, Chung DR, Ko KS, Peck KR, Song JH; Korean Network for Study of Infectious Diseases. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* bacteremia in patients with hematologic malignancy. *Ann Hematol* 2012;91:115-121.
- Eggimann P, Sax H, Pittet D. Catheter-related infections. *Microbes Infect* 2004;6:1033-1042.
- Rosa RG, Goldani LZ, dos Santos RP. Risk factors for multidrug-resistant bacteremia in hospitalized cancer patients with febrile neutropenia: a cohort study. *Am J Infect Control* 2014;42:74-76.

34. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulas V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. *Infection* 2004;32:65-71.
35. Mrázová-Studená M, Drgona L, Spánik S, Krúpová I, Baláz M, Pichna P, Koren P, Sufliarsky J, Mardiak J, Kunová A, Trupl J, Krcmery V Jr. Bacteremia in neutropenic versus nonneutropenic cancer patients: etiology and outcome in 401 episodes. *Neoplasma* 1997;44:314-318.
36. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Goncalves VM. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. *Eur J Clin Microbiol Infect Dis* 2006;25:1-7.
37. Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, Perez FJ, Carratala J. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. *Clin Microbiol Infect* 2015;21:583-590.
38. Marin M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratala J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. *Medicine (Baltimore)* 2014;93:143-149.
39. Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, Marchetti O, de Burghgraeve P, Ramadan S, Pylikkanen L, Ameye L, Paesmans M, Donnelly JP; EORTC Infectious Diseases Group. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). *Clin Infect Dis* 2015;61:324-331.
40. Chan TS, Marcella SW, Gill H, Hwang YY, Kwong YL. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. *J Med Econ* 2016;19:77-83.
41. El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, Granata A, Faucher C, Mohy B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D. Comparison of three distinct prophylactic agents against invasive fungal infections in patients undergoing haplo-identical hematopoietic stem cell transplantation and post-transplant cyclophosphamide. *Mediterr J Hematol Infect Dis* 2015;7:e2015048.
42. Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, Marks DI, Pagliuca A, Solano C, Cragin L, Shaul AJ, Sorensen S, Chambers R, Kantecki M, Weinstein D, Schlamm H. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. *BMC Infect Dis* 2015;15:128.